Research
Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial
BMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h1389 (Published 09 April 2015) Cite this as: BMJ 2015;350:h1389Related articles
- Research Methods & Reporting Published: 01 July 2020; BMJ 370 doi:10.1136/bmj.m2215
See more
- NHS spent 8% more on medicines last yearBMJ November 23, 2016, 355 i6320; DOI: https://doi.org/10.1136/bmj.i6320
- Chronic insomnia: diagnosis and non-pharmacological managementBMJ November 16, 2016, 355 i5819; DOI: https://doi.org/10.1136/bmj.i5819
- A baby with a discharging umbilical lesionBMJ October 26, 2016, 355 i5587; DOI: https://doi.org/10.1136/bmj.i5587
- Authors’ reply to HawkinsBMJ October 18, 2016, 355 i5559; DOI: https://doi.org/10.1136/bmj.i5559
- Anabolic steroid useBMJ October 13, 2016, 355 i5023; DOI: https://doi.org/10.1136/bmj.i5023
Cited by...
- Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial
- Cost-utility analysis of tapering strategies of biologicals in rheumatoid arthritis patients in the Netherlands
- Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial
- Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial
- A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE
- Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial
- Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study
- Non-adherence in non-inferiority trials: pitfalls and recommendations
- Lengthening adalimumab dosing interval in quiescent Crohns disease patients: protocol for the pragmatic randomised non-inferiority LADI study
- Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial)
- Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study
- Three-year cost-effectiveness analysis of the DRESS study: protocolised tapering is key
- Flares in Rheumatoid Arthritis Patients with Low Disease Activity: Predictability and Association with Worse Clinical Outcomes
- Mental health, fatigue and function are associated with increased risk of disease flare following TNF inhibitor tapering in patients with rheumatoid arthritis: an exploratory analysis of data from the Optimizing TNF Tapering in RA (OPTTIRA) trial
- Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis
- Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial
- Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis
- Do non-inferiority trials of reduced intensity therapies show reduced effects? A descriptive analysis
- Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial
- Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: long-term follow-up of the STRASS (Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) randomised controlled trial
- Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis
- Utility of Dose Frequency Adjustment in Tocilizumab Administration for Rheumatoid Arthritis
- What causes a small increase in radiographic progression in rheumatoid arthritis patients tapering TNF inhibitors?
- Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study
- Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions
- The challenge of comorbidity in clinical trials for multiple sclerosis
- Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study)
- Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis